[ad_1]
Moderna has announced the results of its phase 3 trial, which suggest that its vaccine is 94.1% effective against Covid-19 and 100% effective against severe Covid-19.
Best of all, the vaccine was found to be effective in all age groups, genders, and ethnicities.
Stéphane Bancel, CEO of Moderna, said: “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with an efficacy of 94.1% and, more importantly, the ability to prevent disease. Severe COVID-19.
“We believe that our vaccine will provide a powerful new tool that can change the course of this pandemic and help prevent serious illness, hospitalizations and death.”
The results come from Moderna’s Phase 3 study, which enrolled more than 30,000 participants in the US.
They found that there were 196 cases of Covid-19 in the entire test group, 185 of which were in those taking the placebo and 11 of which were receiving the vaccine.
This points to an estimated vaccine efficacy of 94.1%.
The 196 Covid-19 cases included 33 older adults and 42 participants who identified as from diverse communities (including 29 Hispanic or Latino, 6 Black or African American, 4 Asian American, and 3 multiracial participants).
Moderna has now applied for an emergency use authorization from the US Food and Drug Administration.
Bancel added: “We will apply for an Emergency Use Authorization from the FDA today and will continue to move forward with the ongoing reviews that have already started with various regulatory agencies around the world.”
The findings indicate that Moderna’s vaccine could be approved in December, according to Dr. Gillies O’Bryan-Tear, president of Policy and Communications at the College of Pharmaceutical Medicine.
[ad_2]